Mylan NV (MYL)

37.50
0.31 0.83
NASDAQ : Health Care
Prev Close 37.19
Day Low/High 0.00 / 0.00
52 Wk Low/High 33.60 / 54.23
Avg Volume 5.92M
Exchange NASDAQ
Shares Outstanding 535.11M
Market Cap 19.84B
EPS 1.80
P/E Ratio 74.14
Div & Yield N.A. (N.A)

Latest News

Insulin Drug Offers Hope for MannKind

Insulin Drug Offers Hope for MannKind

The stock has taken a beating, but users of Afrezza are loyal to the drug.

Patent Victory Secures Lilly Hold on Cancer Drug Until 2022

Patent Victory Secures Lilly Hold on Cancer Drug Until 2022

An appeals court in Indiana upheld Eli Lilly's patent regarding Alimta, a major cancer drug for Lilly, keeping Teva and other generic drug specialists at bay.

CVS Is the Latest to Rock Mylan's EpiPen Empire

CVS Is the Latest to Rock Mylan's EpiPen Empire

The price of EpiPens has surged about 25% annually since 2007.

Cigna Will No Longer Cover Mylan's EpiPen

Cigna Will No Longer Cover Mylan's EpiPen

Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.

Cigna Defends Abandoning EpiPen Coverage

Cigna Defends Abandoning EpiPen Coverage

Cigna will now encourage patients to use either Impax's or Mylan's generic autoinjector. Impax offers cheaper prices, but can its manufacturing keep up?

I'd Like to Buy the Country an Aircraft -- ICYMI

I'd Like to Buy the Country an Aircraft -- ICYMI

Donald Trump continued to rip corporate America at a press conference Wednesday, but what else did you missy?

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.

U.S. FDA Accepts Biologics License Application (BLA) For Mylan And Biocon's Proposed Biosimilar Trastuzumab

U.S. FDA Accepts Biologics License Application (BLA) For Mylan And Biocon's Proposed Biosimilar Trastuzumab

If Approved, MYL-1401O Has Potential To Be the First Biosimilar Trastuzumab in the U.S.

Mylan Expands OTC Offerings by Acquiring Cold-Eeze

Mylan Expands OTC Offerings by Acquiring Cold-Eeze

Cold-Eeze will become Mylan's largest U.S. over-the-counter brand franchise, and builds upon its $1 billion global OTC business.

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

What Pharma and Health Care Investors Should Watch for at JPM

What Pharma and Health Care Investors Should Watch for at JPM

The largest investor conference for the health care industry kicks off on Monday in San Francisco.

Analysts' Actions -- Adobe, Etsy, Macy's, Western Digital and More

Analysts' Actions -- Adobe, Etsy, Macy's, Western Digital and More

Here are Thursday's top research calls, including upgrades for Etsy and Western Digital, a downgrade for Macy's and new coverage of Adobe.

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.

Allergan Drug Price Hikes Are in Effect, Though Increases Are Modest

Allergan Drug Price Hikes Are in Effect, Though Increases Are Modest

Allergan raises the prices on nine drugs, but keeps the increases reasonable.

Dow, S&P 500 and Nasdaq Close Out 2016 With Strong Gains

Dow, S&P 500 and Nasdaq Close Out 2016 With Strong Gains

Stocks closed lower on the final trading day of 2016, but all three indices close the year with gains.

3 Troubled Companies and How to Play Them in the New Year

3 Troubled Companies and How to Play Them in the New Year

The share prices of Mylan, Sears and Endo International fell dramatically in 2016, and the companies face significant challenges ahead.

Make Sure Your Portfolio Is Protected From Volatility

Make Sure Your Portfolio Is Protected From Volatility

If you use TVIX and VXX put in an above-market limit order, or if you trade options buy calls on the VIX.

Dow, S&P 500 and Nasdaq Fall as Technology Sector Pulls Markets Down

Dow, S&P 500 and Nasdaq Fall as Technology Sector Pulls Markets Down

Stocks moved mostly lower on the final day of trading of 2016, but all three indices are poised to close 2016 with gains.

Stocks Mostly Lower on Last Trading Day of 2016

Stocks Mostly Lower on Last Trading Day of 2016

Stocks were falling below the baseline as 2016 comes to a close.

Watch Beaten-Down Drug Companies, Hospitals in 2017

Watch Beaten-Down Drug Companies, Hospitals in 2017

There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.

Mylan Launches Generic Zovia® Tablets

Mylan Launches Generic Zovia® Tablets

Journal Of The American Medical Association (JAMA) Publishes Mylan And Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal Of The American Medical Association (JAMA) Publishes Mylan And Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

HERITAGE Study Results Demonstrate Equivalent Overall Response Rate for MYL-1401O in Comparison to Branded Trastuzumab